NCT04059198 - Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2019

Primary Completion Date

April 2, 2020

Study Completion Date

April 2, 2020

Conditions

Hepatitis BHBVHepatitis B, Chronic

Interventions

DRUG

Inarigivir soproxil

Inarigivir soproxil 400 mg tablets

DRUG

Tenofovir alafenamide fumarate (TAF)

Tenofovir alafenamide fumarate 25 mg tablet

Trial Locations (2)

Queen Mary Hospital, Hong Kong

Prince of Wales Hospital, Shatin